Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027
Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Key takeaways Why this matters for patients and investors Damora’s approach is aimed squarely at mutant calreticulin (mutCALR)—a well‑validated genetic driver in segments of essential thrombocythemia (ET) and myelofibrosis (MF). Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond
